Kangmei Pharmaceutical Co (600518.SS) Stock Price
Kangmei Pharmaceutical Co Price
Kangmei Pharmaceutical Co (600518.SS) Stock | ISIN CNE0000017M1. The current Kangmei Pharmaceutical Co stock price is 1.41 CNY (2026). Market capitalization is 19.55 B CNY. Kangmei Pharmaceutical Co operates in the Health sector.
Kangmei Pharmaceutical Co stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Kangmei Pharmaceutical Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Kangmei Pharmaceutical Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Kangmei Pharmaceutical Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Kangmei Pharmaceutical Co Price |
|---|
Kangmei Pharmaceutical Co Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Kangmei Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M CNY) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M CNY) |
| NET INCOME (M CNY) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Kangmei Pharmaceutical Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Kangmei Pharmaceutical Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Kangmei Pharmaceutical Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Kangmei Pharmaceutical Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Kangmei Pharmaceutical Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Kangmei Pharmaceutical Co stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Kangmei Pharmaceutical Co Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Kangmei Pharmaceutical Co business model & stock analysis
Kangmei Pharmaceutical Co SWOT Analysis
Strengths
Kangmei Pharmaceutical Co Ltd has several strengths that contribute to its success within the pharmaceutical industry. Firstly, the company has a strong brand presence in the market, which helps build customer trust and loyalty. Secondly, Kangmei Pharmaceutical boasts a diverse portfolio of products, ranging from over-the-counter medicines to prescription drugs, allowing them to cater to a wide range of consumer needs. Additionally, the company has established strategic partnerships with key stakeholders, including hospitals, distributors, and research institutions, enhancing their market reach and competitiveness.
Weaknesses
In spite of its strengths, Kangmei Pharmaceutical faces certain weaknesses that could hinder its growth prospects. One key weakness is its limited international presence, primarily focusing on the domestic Chinese market. This narrow geographical reach may impact the company's potential for global expansion in an increasingly interconnected world. Furthermore, the company relies heavily on third-party suppliers for raw materials, making them susceptible to disruptions in the supply chain, resulting in potential production delays and increased costs.
Opportunities
There are several opportunities that Kangmei Pharmaceutical can leverage to drive further growth. The growing demand for pharmaceutical products in emerging markets presents a significant opportunity for expansion. By targeting these high-growth regions and establishing a solid international presence, Kangmei Pharmaceutical can tap into new revenue streams and diversify its customer base. Additionally, advancements in technology and digital healthcare solutions open doors for the company to enhance its product offerings and engage with customers in innovative ways.
Threats
With opportunities come threats, and Kangmei Pharmaceutical must be aware of potential challenges in the market. One notable threat is the increasing competition from both domestic and international pharmaceutical companies. This intensifying competition may put pressure on Kangmei Pharmaceutical to differentiate its products and maintain competitive pricing strategies. Additionally, the ever-changing regulatory landscape and stringent government policies in the pharmaceutical industry can pose challenges that the company must navigate effectively to ensure compliance and avoid penalties.
Kangmei Pharmaceutical Co Eulerpool Fair Value
Kangmei Pharmaceutical Co historical P/E ratio, EBIT multiple, and P/S ratio
Kangmei Pharmaceutical Co annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Kangmei Pharmaceutical Co shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Kangmei Pharmaceutical Co Dividend History
19 years of dividend payments
Kangmei Pharmaceutical Co dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
EESG©
Eulerpool ESG Scorecard© for the Kangmei Pharmaceutical Co stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Kangmei Pharmaceutical Co shareholder structure
| % | Name |
|---|---|
25.31338% | |
3.71651% | |
0.76657% | |
0.74684% | |
0.73441% | |
0.70808% | |
0.68511% | |
0.67353% | |
0.57283% | |
0.20175% |
Kangmei Pharmaceutical Co Executives and Management Board
Mr. Zhijian Lai
(55)Chairman of the Board · since 2022
Mr. Guibo Gong
(50)Chief Financial Officer, Deputy General Manager · since 2020
Mr. Yunfeng Zhou
(43)Chief Compliance Officer, Deputy General Manager, Secretary of the Board, Director · since 2020
Mr. Guoxiong Ou
(57)General Manager, Director · since 2021
Mr. Qiyun Chen
(47)Deputy General Manager
Kangmei Pharmaceutical Co Supply Chain
Frequently asked questions about Kangmei Pharmaceutical Co
The business model of Kangmei Pharmaceutical Co Ltd revolves around pharmaceutical manufacturing, sales, and distribution. As a leading Chinese pharmaceutical company, Kangmei focuses on research, production, and marketing of a wide range of medicinal products. With a comprehensive product portfolio covering areas such as Chinese herbal medicine, prescription drugs, and health products, Kangmei delivers accessible and affordable healthcare solutions to consumers. By emphasizing technological innovation, quality control, and strategic partnerships, Kangmei seeks to constantly improve its product offering, expand market reach, and enhance overall customer satisfaction.
Kangmei Pharmaceutical Co stock
Kangmei Pharmaceutical Co Peer Group
Kangmei Pharmaceutical Co Ticker
Kangmei Pharmaceutical Co FIGI
All fundamentals and in-depth analysis of Kangmei Pharmaceutical Co
Our stock analysis for Kangmei Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kangmei Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.